A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
23
03
2023
revised:
08
06
2023
accepted:
30
06
2023
pmc-release:
12
07
2024
medline:
13
11
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a 4-criterion framework for assessing interactions that includes statistical, qualitative, biological, and practical approaches. We present the application of this framework in an ovarian cancer setting because this is an important step in developing more accurate risk stratification models. Using data from 9 case-control studies in the Ovarian Cancer Association Consortium, we conducted a comprehensive analysis of interactions among 15 unequivocal risk and protective factors for ovarian cancer (including 14 non-genetic factors and a 36-variant polygenic score) with age and menopausal status. Pairwise interactions between the risk/protective factors were also assessed. We found that menopausal status modifies the association among endometriosis, first-degree family history of ovarian cancer, breastfeeding, and depot-medroxyprogesterone acetate use and disease risk, highlighting the importance of understanding multiplicative interactions when developing risk prediction models.
Identifiants
pubmed: 37436712
pii: 7223199
doi: 10.1093/jnci/djad137
pmc: PMC10637032
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1420-1426Subventions
Organisme : Wellcome Trust
ID : 076113
Pays : United Kingdom
Organisme : CIHR
ID : MOP-86727
Pays : Canada
Organisme : NIH HHS
ID : CA1X01HG007491-01
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058598
Pays : United States
Organisme : NCI NIH HHS
ID : U19-CA148112
Pays : United States
Organisme : NHGRI NIH HHS
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
JAMA Netw Open. 2022 Feb 1;5(2):e2147343
pubmed: 35138400
Cytokine. 2012 May;58(2):133-47
pubmed: 22349527
J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):301-21
pubmed: 18368558
PLoS Med. 2013;10(7):e1001492
pubmed: 23935463
Endocr Rev. 2019 Apr 1;40(2):369-416
pubmed: 30496379
Obstet Gynecol Clin North Am. 1997 Jun;24(2):235-58
pubmed: 9163765
Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):103-11
pubmed: 10667470
Cancer Prev Res (Phila). 2019 Jun;12(6):401-412
pubmed: 31015198
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
Ann Epidemiol. 2011 Mar;21(3):188-96
pubmed: 21109450
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):671-676
pubmed: 25623732
Am J Epidemiol. 2016 Oct 15;184(8):579-589
pubmed: 27698005
Obstet Gynecol. 2016 May;127(5):828-836
pubmed: 27054934
Int J Cancer. 2001 Nov 20;95(6):370-4
pubmed: 11668519
J Med Genet. 2022 Jul;59(7):632-643
pubmed: 34844974
J Natl Cancer Inst. 2021 Mar 1;113(3):301-308
pubmed: 32766851
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):880-90
pubmed: 23462924
Climacteric. 2018 Jun;21(3):249-255
pubmed: 29609503
Am Fam Physician. 2009 Sep 15;80(6):609-16
pubmed: 19817326
JAMA Oncol. 2020 Jun 1;6(6):e200421
pubmed: 32239218
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62
pubmed: 23404857
Cancer Causes Control. 2000 Jul;11(6):477-88
pubmed: 10880030
Breast Cancer Res Treat. 2014 May;145(1):165-75
pubmed: 24647890
Int J Cancer. 2017 Dec 15;141(12):2392-2399
pubmed: 28748634
Epidemiology. 2020 May;31(3):402-408
pubmed: 32028322
Epidemiology. 2005 Jul;16(4):508-15
pubmed: 15951669
Obstet Gynecol. 2011 May;117(5):1042-1050
pubmed: 21471855
Lancet. 2008 Jan 26;371(9609):303-14
pubmed: 18294997
Cancer Causes Control. 2010 Oct;21(10):1731-41
pubmed: 20559705
Breast Cancer Res Treat. 2010 Jan;119(1):221-32
pubmed: 19370414
Int J Cancer. 2008 Jan 1;122(1):170-6
pubmed: 17721999
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Nat Genet. 2017 Jun;49(6):834-841
pubmed: 28436984
Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935
pubmed: 33619020
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1094-100
pubmed: 25873577
Br J Cancer. 2018 Apr;118(8):1123-1129
pubmed: 29555990
Drugs. 2009;69(6):649-75
pubmed: 19405548
Cancer Causes Control. 2012 Dec;23(12):1985-94
pubmed: 23065074
Obstet Gynecol. 2018 May;131(5):909-927
pubmed: 29630008
Genet Med. 2006 Sep;8(9):571-5
pubmed: 16980813
Cancer Res. 2005 Jul 1;65(13):5974-81
pubmed: 15994977
BMC Womens Health. 2011 Sep 23;11:40
pubmed: 21943063
Natl Health Stat Report. 2018 Jul;(113):1-17
pubmed: 30248009